NYSE:EHC - Encompass Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $98.11
  • Forecasted Upside: 42.05 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$69.07
▲ +1.29 (1.90%)

This chart shows the closing price for EHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Encompass Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EHC

Analyst Price Target is $98.11
▲ +42.05% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Encompass Health in the last 3 months. The average price target is $98.11, with a high forecast of $110.00 and a low forecast of $88.00. The average price target represents a 42.05% upside from the last price of $69.07.

This chart shows the closing price for EHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Encompass Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/28/2020
  • 1 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/27/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/25/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/20/2021
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2021TruistLower Price TargetBuy$100.00 ➝ $88.00Medium
10/13/2021Truist SecuritiesLower Price TargetBuy$100.00 ➝ $88.00Medium
9/23/2021UBS GroupInitiated CoverageBuy$98.00Low
8/2/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$95.00 ➝ $107.00Medium
7/29/2021Royal Bank of CanadaBoost Price TargetOutperform$102.00 ➝ $104.00Low
7/29/2021Credit Suisse GroupBoost Price TargetOutperform$96.00 ➝ $98.00Medium
7/29/2021Deutsche Bank AktiengesellschaftBoost Price TargetBuy$104.00 ➝ $110.00Medium
7/2/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$87.00 ➝ $104.00High
4/29/2021Raymond JamesBoost Price TargetOutperform$90.00 ➝ $95.00Low
4/29/2021MizuhoBoost Price TargetBuy$90.00 ➝ $94.00N/A
1/28/2021Credit Suisse GroupLower Price TargetOutperform$97.00 ➝ $92.00Low
1/28/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$70.00 ➝ $87.00N/A
1/15/2021UBS GroupBoost Price TargetBuy$85.00 ➝ $106.00N/A
12/18/2020MizuhoBoost Price TargetBuy$87.00 ➝ $90.00N/A
11/30/2020Raymond JamesBoost Price TargetOutperform$78.00 ➝ $90.00Low
11/23/2020BarclaysUpgradeOverweight$96.00Low
11/2/2020Credit Suisse GroupLower Price TargetOutperform$89.00 ➝ $85.00Medium
11/2/2020Raymond JamesLower Price TargetOutperform$86.00 ➝ $78.00Low
10/30/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$83.00 ➝ $70.00N/A
9/10/2020Credit Suisse GroupReiterated RatingBuyN/A
7/27/2020Jefferies Financial GroupLower Price TargetBuy$90.00 ➝ $86.00Medium
6/10/2020Credit Suisse GroupReiterated RatingBuy$89.00N/A
5/29/2020MizuhoLower Price TargetBuy$90.00 ➝ $87.00N/A
5/1/2020UBS GroupLower Price TargetBuy$96.00 ➝ $90.00Low
4/30/2020Raymond JamesLower Price TargetOutperform$90.00 ➝ $86.00High
4/20/2020Royal Bank of CanadaReiterated RatingBuy$84.00N/A
4/20/2020BMO Capital MarketsBoost Price TargetOutperform$66.00 ➝ $83.00N/A
4/17/2020Credit Suisse GroupReiterated RatingBuy$89.00N/A
3/6/2020UBS GroupBoost Price TargetBuy$95.00 ➝ $96.00Medium
3/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$73.00 ➝ $83.00Low
3/5/2020Robert W. BairdBoost Price TargetOutperform$85.00 ➝ $100.00High
3/5/2020MizuhoBoost Price TargetBuy$87.00 ➝ $90.00Low
3/5/2020BMO Capital MarketsBoost Price TargetOutperform$88.00 ➝ $95.00N/A
3/5/2020StephensBoost Price TargetOverweight$91.00 ➝ $100.00Low
2/10/2020Piper SandlerBoost Price Target$77.00 ➝ $89.00N/A
2/10/2020SunTrust BanksBoost Price TargetBuy$90.00 ➝ $100.00Medium
2/10/2020MizuhoBoost Price TargetBuy$84.00 ➝ $87.00Medium
2/10/2020MizuhoReiterated RatingBuy$84.00 ➝ $87.00N/A
1/22/2020JMP SecuritiesBoost Price TargetOutperform$85.00N/A
1/16/2020MizuhoReiterated RatingBuy$76.00 ➝ $84.00N/A
1/15/2020Credit Suisse GroupBoost Price TargetOutperform$77.00 ➝ $89.00Medium
1/14/2020BMO Capital MarketsBoost Price TargetOutperform$85.00 ➝ $88.00Medium
1/13/2020Jefferies Financial GroupBoost Price Target$80.00 ➝ $90.00N/A
1/10/2020UBS GroupBoost Price TargetBuy$80.00 ➝ $87.00High
12/11/2019Wells Fargo & CompanyDowngradeMarket Perform ➝ Underperform$68.00N/A
10/21/2019StephensInitiated CoverageOverweight$77.00N/A
9/17/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$70.00Low
9/16/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$70.00N/A
9/6/2019Bank of AmericaUpgradeBuyLow
8/12/2019Craig HallumReiterated RatingBuy$81.00 ➝ $76.00N/A
8/7/2019Royal Bank of CanadaReiterated RatingBuyN/A
7/31/2019Piper Jaffray CompaniesSet Price TargetBuy$77.00N/A
7/31/2019Raymond JamesLower Price TargetOutperform$80.00 ➝ $75.00Medium
6/27/2019BMO Capital MarketsInitiated CoverageOutperform$72.00High
5/30/2019BarclaysUpgradeEqual Weight ➝ Overweight$68.00 ➝ $70.00Low
12/20/2018Jefferies Financial GroupInitiated CoverageBuy ➝ BuyMedium
12/14/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$75.00High
11/15/2018UBS GroupInitiated CoverageBuy$86.00Medium
7/26/2018MizuhoReiterated RatingBuy$82.00Low
7/26/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightLow
7/26/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$66.00 ➝ $80.00Low
7/20/2018SunTrust BanksReiterated RatingBuy$82.00N/A
4/30/2018Royal Bank of CanadaBoost Price TargetOutperform$69.00Medium
4/30/2018Robert W. BairdBoost Price TargetOutperform$59.00 ➝ $66.00Medium
4/30/2018Craig HallumBoost Price TargetBuy$63.00 ➝ $71.00Medium
4/30/2018Craig HallumReiterated RatingBuy$63.00 ➝ $71.00N/A
4/30/2018Robert W. BairdReiterated RatingOutperform$59.00 ➝ $66.00N/A
4/27/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $66.00Medium
4/17/2018SunTrust BanksReiterated RatingBuy$70.00Low
3/29/2018MizuhoInitiated CoverageBuy ➝ Buy$62.00N/A
3/29/2018MizuhoReiterated RatingBuy ➝ Buy$62.00N/A
3/16/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$61.00 ➝ $65.00Low
3/16/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$61.00 ➝ $65.00N/A
3/1/2018Piper Jaffray CompaniesReiterated RatingHoldHigh
3/1/2018Royal Bank of CanadaBoost Price TargetOutperform$64.00N/A
2/27/2018Credit Suisse GroupReiterated RatingOutperformHigh
2/27/2018StephensSet Price TargetBuy$62.00N/A
2/27/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $61.00N/A
1/30/2018Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market Perform$56.00N/A
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$58.00N/A
1/12/2018StephensReiterated RatingBuy$55.00N/A
1/12/2018Robert W. BairdReiterated RatingBuy$59.00N/A
1/9/2018Craig HallumReiterated RatingBuy$54.00 ➝ $60.00Low
1/4/2018Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
12/21/2017SunTrust BanksSet Price TargetBuy$58.00Low
11/21/2017William BlairReiterated RatingOutperformN/A
11/15/2017Royal Bank of CanadaReiterated RatingBuyN/A
11/2/2017MizuhoUpgradeNeutral ➝ Buy$55.00N/A
10/9/2017Robert W. BairdReiterated RatingBuy$55.00N/A
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$50.00High
9/7/2017KeyCorpReiterated RatingHoldLow
9/6/2017Royal Bank of CanadaReiterated RatingBuy$55.00Medium
8/31/2017StephensInitiated CoverageOverweight$53.00High
8/3/2017Piper Jaffray CompaniesReiterated RatingHold$50.00Low
7/10/2017MizuhoBoost Price TargetNeutral ➝ Neutral$44.00 ➝ $47.00Medium
7/5/2017Royal Bank of CanadaReiterated RatingBuy$53.00High
6/15/2017KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
5/1/2017BarclaysReiterated RatingUnderweight$44.00 ➝ $46.00Low
2/27/2017Royal Bank of CanadaBoost Price TargetOutperform$48.00 ➝ $50.00N/A
2/27/2017Royal Bank of CanadaReiterated RatingOutperform$48.00 ➝ $50.00N/A
2/22/2017StephensUpgradeEqual Weight ➝ OverweightN/A
2/22/2017MizuhoBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $44.50N/A
2/13/2017Craig HallumInitiated CoverageBuy$48.00N/A
1/3/2017Piper Jaffray CompaniesInitiated CoverageNeutral$45.00N/A
1/3/2017Royal Bank of CanadaReiterated RatingBuy$48.00N/A
11/9/2016MizuhoDowngradeBuy ➝ NeutralN/A
10/31/2016Royal Bank of CanadaReiterated RatingOutperform$46.00 ➝ $48.00N/A
10/31/2016Royal Bank of CanadaBoost Price TargetOutperform$46.00 ➝ $48.00N/A
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/22/2021
  • 14 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/21/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 4 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 4 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Encompass Health logo
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provides rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations. The Home Health and Hospice segment provides Medicare-certified home nursing, specialized home care and in-home services. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.
Read More

Today's Range

Now: $69.07
Low: $67.65
High: $69.27

50 Day Range

MA: $73.27
Low: $67.05
High: $77.49

52 Week Range

Now: $69.07
Low: $60.51
High: $89.68

Volume

692,300 shs

Average Volume

603,187 shs

Market Capitalization

$6.87 billion

P/E Ratio

17.99

Dividend Yield

1.65%

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Encompass Health?

The following sell-side analysts have issued stock ratings on Encompass Health in the last twelve months: Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Mizuho, Raymond James, Royal Bank of Canada, Truist, Truist Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for EHC.

What is the current price target for Encompass Health?

9 Wall Street analysts have set twelve-month price targets for Encompass Health in the last year. Their average twelve-month price target is $98.11, suggesting a possible upside of 42.3%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting EHC will reach $110.00 in the next twelve months. Truist has the lowest price target set, forecasting a price of $88.00 for Encompass Health in the next year.
View the latest price targets for EHC.

What is the current consensus analyst rating for Encompass Health?

Encompass Health currently has 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EHC will outperform the market and that investors should add to their positions of Encompass Health.
View the latest ratings for EHC.

How do I contact Encompass Health's investor relations team?

Encompass Health's physical mailing address is 3660 Grandview Pkwy Ste 200, BIRMINGHAM, AL 35243-3332, United States. The company's listed phone number is (205) 967-7116 and its investor relations email address is [email protected] The official website for Encompass Health is www.healthsouth.com.